As we gear up for the final stretch of the year, BioLizard enters the autumn season with renewed energy and momentum. The company has delivered a standout first half of 2025, marked by international recognition, groundbreaking AI innovation, and strategic expansion. With major awards, new product ...
.jpg)
.jpg)
For decades, pharmaceutical innovation has faced a paradox: while technology has advanced, drug development has grown increasingly inefficient. How come you might ask? This paradox is described in Eroom’s Law. Named as the reverse of “Moore’s Law”, which describes exponential gains in computing ...
VLAIO grant to fund development of new AI application, using large language models (LLMs) to search, extract and structure key insights from vast scientific datasets, significantly reducing review time and knowledge extraction State-of-the-art solution will further expand capabilities of ...
Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech Showcase during JP Morgan Week (Jan 13-15, 2025) in San Francisco Discover Bio|Verse® Navigator, ...
Bio|Verse Navigator can accelerate data exploration and interpretation workflows multifold, reducing time-to-insight for researchers. The application combines advanced BioLizard’s bioinformatics expertise in handling various customer datasets with powerful visual analytics, capable of exploring ...
